Subdural Hematoma During Lorlatinib-Induced Regression of Leptomeningeal Carcinomatosis with Suspected Dural Involvement in ALK-Positive Lung Adenocarcinoma.

Authors

Taiyo Kakefuda, Katsuyoshi Tomomatsu, Kaiki Suzuki, Kohei Umemoto, Yukihiro Horio, Jun Nishiyama, Naoki Hayama, Yoko Ito, Koichiro Asano, Tsuyoshi Oguma

Published in

Internal medicine (Tokyo, Japan). Oct 08, 2026. Epub Oct 08, 2026.

Abstract

Lorlatinib, a central nervous system (CNS)-penetrant anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, is effective in treating leptomeningeal carcinomatosis. A woman in her 30s with ALK-positive lung adenocarcinoma and leptomeningeal carcinomatosis developed an asymptomatic subdural hematoma (SDH) 7 weeks after starting lorlatinib, coinciding with the regression of leptomeningeal lesions. The posterior extent of the SDH appeared to be partially contiguous with the focal dural enhancement observed before treatment. Lorlatinib was continued under multidisciplinary supervision. The hematoma resolved without surgery and did not recur during the 6 years of treatment. SDH may occur during the rapid regression of leptomeningeal disease with suspected dural involvement under CNS-penetrant ALK inhibitor therapy.

PMID:
42844192
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.